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primitive neuroectodermal tumor of cerebellum, consti-
tutes 20% of all childhood primary neoplasms of the 
central nervous system (cNS).3 This cerebellar neo-
plasm arises in the posterior fossa 4 originating from the 
granule neuron precursor cells (gNPs) in the external 
granular layer (egl) at the surface of the developing 
cerebellum.5 MB is diagnosed in patients under 15 
years of age (70% of cases), with a peak age at presenta-
tion in 3-6 years old children.6 MB exhibits a tendency 
Primary brain tumors are the second most common type of pediatric cancer causing morbidity and mor-
tality. The incidence of brain tumors for patients be-
tween 0 and 19 years ranges from 3.3 to 4.5 cases per 
100,000 patients/year.1 The therapy for pediatric brain 
tumors is still challenging because of the poor response 
to conventional cytotoxic chemotherapeutics agents and 
radiation therapy with the therapy-related morbidity that 
is a huge issue in children.2 Medulloblastoma (MB), a 
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a B S T r a c T
BACKGROUND: Medulloblastoma is a cerebellar neoplasia of the central nervous system. Four molecular subgrups have been identified 
(MBWNT, MBShh, MBgroup3 and MBgroup4) with distinct genetics and clinical outcome. among these, MBgroup3-4 are highly metastatic with the worst 
prognosis. The current standard therapy includes surgery, radiation and chemotherapy. Thus, specific treatments adapted to cure those different 
molecular subgroups are needed. The use of orthotopic xenograft models, together with the non-invasive in vivo biolumiscence imaging (Bli) 
technology, is emerging during preclinical studies to test novel therapeutics for medulloblastoma treatment.
METHODSː Orthotopic MB xenografts were performed by injection of Daoy-luc cells, that had been previously infected with lentiviral particles 
to stably express luciferase gene, into the fourth right ventricle of the cerebellum of ten nude mice. For the implantation, specific stereotactic 
coordinates were used. Seven days after the implantation the mice were imaged by acquisitions of bioluminescence imaging (Bli) using iViS 
3D Illumina Imaging System (Xenogen). Tumor growth was evaluated by quantifying the bioluminescence signals using the integrated fluxes of 
photons within each area of interest using the living images Software Package 3.2 (Xenogen-Perkin elmer). finally, histological analysis using 
hematoxylin-eosin staining was performed to confirm the presence of tumorigenic cells into the cerebellum of the mice.
RESULTSː We describe a method to use the in vivo bioluminescent imaging (Bli) showing the potential to be used to investigate the potential 
antitumorigenic effects of a drug for in vivo medulloblastoma treatment. We also discuss other studies in which this technology has been applied 
to obtain a more comprehensive knowledge of medulloblastoma using orthotopic xenograft mouse models.
CONCLUSIONSː There is a need to develop patient’s derived-xenograft (PDX) model systems to test novel drugs for medulloblastoma treat-
ment within each molecular sub-groups with a higher predictive value. here we show how this technology should be applied with hopes on 
generations of new treatments to be applied then in human.
(Cite this article as: asadzadeh f, ferrucci V, de antonellis P, Zollo M. In vivo bioluminescence imaging using orthotopic xenografts towards patient’s 
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tumor microenvironment with the exception of T-cell 
populations due to the use implantation in athymic nude 
mice.15
however, the use of murine xenograft using human 
tumorigenic cell lines has a variable predictive power 
during the translation of cancer therapeutics into clinics. 
a more clinically predictive models of human cancer 
is obtained when primary tumors are used as an ortho-
topic xenograft (also known as Patient-derived Xeno-
grafts or PdXs).16 orthotopic PdX models are based on 
the transfer of primary tumors directly from the patient 
into the organ of choice of an immunodeficient mouse.16 
This orthotopic PdX models accurately mimic the hu-
man tumors from which they are derived in terms of 
histology and gene expression profiles from mice to pa-
tients. The major challenges of these orthotopic models 
(xenograft and PdX) for brain tumors are due to the 
surgical technique for tumor implantation and the dif-
ficulty for following tumor growth, during the early 
stages of tumorigenesis.
Therefore, the use of in vivo imaging technologies 
is of importance to follow tumorigenesis using these 
orthotopic xenograft and PdX models during preclini-
cal studies. Several tecniques have been recently de-
scribed: X-ray, computed tomography (cT), ultrasound 
(uS), magnetic resonance imaging (Mri), single pho-
ton emission computed tomography (SPecT), positron 
emission tomography (PeT) and bioluminescence im-
aging (Bli).21
among these, in vivo Bli technology is emerging as 
a “non-invasive” detection method that allows disease-
specific treatment strategies to be evaluated during pre-
clinical studies.22 Bli is a technique based on the de-
tection and quantification of the light emitted from the 
conversion of chemical into photon energy. Biolumines-
cence signal is produced by the aTP-dependent conver-
sion of luciferin by luciferase enzyme into the light-
emitting product oxyluciferin, that is then externally 
captured by the highly sensitive charge-coupled device 
(ccd) camera.23 in details, in vivo bioluminescent im-
aging (Bli) detects bioluminescent light produced by 
several luciferase enzymes, such as Firefly, Renilla, 
gaussia, Metridia, Vargula, or bacterial luciferase in the 
presence of Luciferins. Among these, Firefly Luciferase 
(luc) has been widely used. it catalyzes the oxidation 
of Luciferin (D-(−)-2-(60-hydroxy-20 benzothiazolyl)-
thiazone-4-carboxylic acid) in presence of molecular 
to metastasize in the subarachnoid space in about 35% 
of children with MB.4 Studies of transcriptional profil-
ing of primary MB indicated the existence of four dis-
tinct molecular clonal genetic subgroups differing from 
each other with respect to genetics, epigenetics, gene 
expression, histology, and clinical outcome: MBWNT, 
MBShh, MBgroup3 and MBgroup4.7, 8 Taylor et al.,8 re-
ported the current consensus correlating the biological 
features of the four molecular subgroups to patient de-
mographics, tumor-cell histology and most importantly 
patient outcome. Within these molecular subgroups, the 
MBWNT group have favourable patient outcome with an 
overall survival rates >95%. The MBShh group shows 
intermediate prognosis, with an overall survival rates 
from 60% to 80% and with low frequency to metasta-
tize.8 instead, MBgroup3/4, are highly metastatic show-
ing activation of different pathways including Myc, 
TGF-β and Otx2 signaling for MBgroup3, or mutations 
in cdK6 and MycN oncogenes for MBgroup4.7, 9, 10 
MBgroup3 accounts for a quarter of all MB, and carries 
the worst prognosis, while MBgroup4 is the most com-
mon MB with an intermediate prognosis.8, 11 The mo-
lecular stratification of patients with MB has not yet 
been routinely implemented in the clinic, and the use 
of targeted therapy is still at the beginning.11, 12 To date, 
the standard therapy includes initial surgery followed 
by radiation and chemotherapy. despite the acceptable 
survival rates with current multimodality treatment, pa-
tients encounter devastating morbidity, including per-
manent neurocognitive dysfunctions 13 and secondary 
malignancies.14 Thus, new treatment options, more ef-
fective and less toxic, are needed.
despite new insight into the biology of cancer, novel 
therapeutic strategies fail. This is mostly due to the poor 
clinical predictive power of the model systems used to 
test the novel antitumorigenic drugs. When evaluating 
our approach to target discovery, we should consider if 
the drugs are being tested on model systems that have a 
clinical predictive power.
orthotopic MB xenograft murine models, consisting 
in human MB tumorigenic cells transplanted into the 
cerebellum of immunocompromised mice,15 have been 
shown to have advantages in evaluating the responses 
to a drug 15 with respect to those genetically engineered 
MB mouse (geM) models.5, 15-20 in fact, “orthotopic” 
tumor xenografts retain the genetic and epigenetic ab-
normalities found in MB patients and reproduce the 
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the appropriate amount of viral particles (50 multiplic-
ity of infection [MOI]/cell) encoding Firefly Luciferase 
gene (redifect red-fluc-Puromycin, clS960002, by 
Perkin elmer, Waltham, Ma, uSa) was added to the 
medium. after 3 days, the medium was replaced and 
the Puromycin dihydrochloride (a1113802, Thermo 
Fisher) was added at a final concentration of 0.5 ug/mL 
to select only the transduced cells.
ethical approval for mouse use: Ministero della San-
ità 546/2015 Pr released to the director of Studies, 
Massimo Zollo, 19/06/2015, art. 31 d.lgs. 26/2104.
Ortotopic xenograft implantation into fourth right ven-
tricle of cerebellum of nude mice
To establish intracerebellar daoy-luc xenograft 
models, 6 weeks old nude mice were anesthetized with 
Tribromoethanol (avertin®) [Sigma-aldrich, Saint 
louis, Mo, uSa #T4, 840-2] (50 mg/kg); after this, the 
mice were placed onto a stereotactic frame by hooking 
its incisors onto the frame hold. a small skin incision (1 
mm) and a burr hole (0.7 mm in diameter) were created 
with a microsurgical drill (fine Science Tools, foster 
city, ca, uSa). daoy-luc cells (105) were suspended 
in 5 μL PBS and injected slowly, through the burr hole, 
into the right cerebellar hemisphere (stereotactic co-
ordinates from bregma, anteroposterior 5.5 mm; right 
lateral 2.1 mm; dorsoventral 5.0 mm), with a steady 
force in a 30 second time frame of the recipient, using 
a 10-al, 26-gauge hamilton gastight Model 1701rN 
(Sigma-aldrich) syringe needle that was inserted per-
pendicular to the cranial surface. The needle was left 
in its place after completion of injection for additional 
two minutes and then the needle and syringe were re-
moved, and the incision was sutured using Safil poly-
glycolic acid synthetic absorbable suture (6/0). later, 
mice were kept on a warming blanket after the surgery 
to help maintain its body temperature. Mobility and re-
spiratory patterns were observed continuously and once 
the mouse had recovered from anesthesia, were place in 
a sterile housing cage. The animals were then monitored 
daily for development of potential neurological deficits.
Acquisition of BLI
Seven days after the implantation of the cells, the 
mice were imaged, and tumor growth was evaluated by 
oxygen and adenosine triphosphate to generate co2, 
aMP, PPi, oxyluciferin emitting a yellow-green light at 
a wavelength of 562 nm. The spectrum of the emitted 
light can be revealed and quantified with ultra-sensitive 
cooled ccd cameras.23, 24 indeed, Bli, exhibiting mini-
mal background signals, is a highly sensitive technique 
for studying cell proliferation and migration in vivo in 
a specific anatomical site.25, 26 Moreover, the lumines-
cence is due to an aTP-dependent reaction, and there-
fore, only the metabolically active cancer cells provide 
bioluminescence production. for the above reasons, 
Bli offers an effective and valuable preclinical instru-
ment to investigate distinct biological processes and to 
explore human diseases, including tumors growth and 
metastases. importantly, due to the lack of invasiveness, 
this Bli approach can reduce the number of animals 
during the experiments. Moreover, after mice sacrifice, 
the experiments can be also performed ex vivo using 
Bli, thus eliminating pain, suffering or distress in the 
experimental protocols. This is in agreement with the 
ethical use of animals in testing (3rS).27 This technol-
ogy has been applied to study the potential therapeutics 
in several brain tumors, including MB.28-31
here, we focus our attention on the role of Bli meth-
od to study MB using orthotopic xenograft mice mod-
els. This technology is of importance to study MB pro-
gression and to evaluate the potential antitumorigenic 
effects of novel and less toxic compounds. This method 
will also allow novel drugs, including natural agents 
with a mean of chemo-adjuvant therapy, to be tested for 
pediatric MB treatment.
Materials and methods
Generation of Daoy-Luc cells
MBShh daoy cell lines were grown in Minimum es-
sential Medium (euroclone, Milan, italy) supplemented 
with 10 % (v/v) fetal bovine serum (euroclone), 2 mM 
l-glutamine (euroclone), and 1 % (v/v) antibiotics 
(10,000 u/ml penicillin, 10 mg/ml streptomycin (euro-
clone). The cells were grown at 37° C in a humidified 
atmosphere of 95% air and 5% co2 (v/v).
for lentiviral infection, daoy cells (204) were plated 
in complete medium into 1 well of a 24 well-plate for 
24 hr; the medium was then replaced with 500 µl of 
fresh complete medium containing hexadimethrine bro-
mide (Polybrene) at a final concentration of 4 µg/mL; 
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Firefly Luciferase (Luc) gene by using Lentiviral par-
ticle (redifect red.fluc-Puro, clS960002, Perkin el-
mer). This allowed us to select only Firefly Luciferase 
positive cells (daoy-luc), which were then implanted 
into the cerebellum of ten nude mice (as described in de-
tails in Material and Methods section). daoy-luc cells 
were directly injected into the fourth right ventricle of 
cerebellum using the following stereotactic coordinates 
from Bregma: anteroposterior 5.5 mm, right lateral 2.1 
mm, dorsoventral 5.0 mm (as described in “Materials 
and methods” section).
Tumor growth was monitored from the time of im-
plantation (T0) up to 4 weeks (T4) through in vivo bio-
luminescent imaging (Bli), as shown in figure 1a, B. 
BLI images were captured every week, as clearly shown 
in figure 1B. Subsequently, the number of photons/ 
seconds in the region of interest (roi) was also mea-
sured to quantify the Bli signals (see Table i for Bli 
values) in order to perform statistical analysis using the 
analytics software SPSS, as shown in figure 1c. our 
statistical analyses (N. 10 mice group dataset) dem-
onstrated that Bli signals gradually increase from the 
second week (T2) up to the fourth week (T4) after the 
implantation. In details, statistically significant differ-
ences in tumor growth were found in the comparison 
between those groups of mice analysed between T2, T3, 
T4 and T0 (P<0.017, P<0.000, P<0.000). There were 
no differences when BLI values taken in the first week 
(T1) compared with those from T0. This is due to a 
temporary loss of engraftment and some cellular deaths 
observed of those cells implanted in early phases of tu-
morigenesis in the recipient cerebellum.
After four weeks, mice were sacrificed due to evi-
dent signs of illness and pain for the tumor burden 
evaluated by photon/sec emission data. The brain and 
the cerebellum were collected and tumor sections were 
used to perform histopathological analysis. The pres-
ence of tumorigenic cells within the cerebellum was 
confirmed through hematoxylin/eosin staining, as 
shown in figure 1d.
Discussion
our data present a non-invasive technology “Bli” as 
an efficient method to follow the tumor progression in 
vivo. importantly, the use of Bli imaging technology, 
applied to these orthotopic xenograft models, permits to 
acquisitions of Bli using iViS 3d illumina imaging 
System (Xenogen/caliper).
for the acquisitions, the mice were anesthetized by in-
halational of Isofluorane and D-Luciferin (122799, Per-
kin elmer) (15 mg/ml stock) was intra peritoneally in-
jected (100 μl per 10 g body weight) after 5 minutes from 
Luciferin injection, they were imaged for 1.30 min. Sev-
eral acquisitions were made per mouse till each mouse 
exhibits its peak of photon emission. Then n. 5 total ac-
quisitions (weekly for a total of 28 days of analysis), near 
to the peak value, for each mouse were analyzed.
To quantify the bioluminescence, the integrated 
fluxes of photons (photons per sec) within each area of 
interest were determined using the living images Soft-
ware Package 3.2 (Xenogen-Perkin elmer).
Histological analyses with hematoxylin-eosin stainings
Following sacrifice, fresh brain was removed from 
the skull, washed in iced phosphate buffer saline (PBS; 
ECB4004L, Euroclone, Pero, Milan, USA), fixed with 
4% paraformaldehyde (Pfa, 387507, carlo erba, Mi-
lan, Italy) and embedded into paraffin (Lab-O-Wax, 
r0040, hysto-line laboratories, Milan, italy). Sections 
of 3 μm in thickness were cut through the cerebellum 
using a microtome (rM2125rT, leica, Wetzlar, ger-
many). The sections were then deparaffinised using 
Bioclear (06-1782d, Bio-optica, Milan, italy) and 
placed in a solution consisting of absolute Methanol 
(32213, Sigma-aldrich) and 0.3% hydrogen peroxide 
(216763, Sigma-aldrich) for 15 min. They were then 
washed in PBS and processed with hematoxylin-eosin 
staining for microscopic examimation. Subsequently, 
the slides were washed in PBS, dehydrated with alco-
hol andxylene, and mounted with cover slips using a 
permanent mounting medium (Permount, ProSciTech, 
Kelso, australia). Micrographs were taken with a leica 
dfc320 digital camera.
Results
MB tumorigenesis is followed in vivo through BLI in 
orthotopic xenografts
The use of Bli technology is of importance to un-
ravel MB biogenesis and to test the clinical response 
to novel drugs in different MB mice models. for this 
purpose, MBShh daoy cells were engineered to express 
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Bli technology has been applied to several orthotop-
ic MB xenograft models to study in vivo the response 
to novel therapeutic regimens, including natural agents, 
study the response to novel therapeutic regimens in vivo 
in terms of tumor growth/regression by quantifying the 
Bli results (roi).
figure 1.—orthotopic xenograft of MBShh model. a) representative scheme for the orthotopic xenograft experiment. MBShh daoy-luc cells 
(105 cells) were implanted in the cerebellum of nude mice at T0. Starting after 7 days from the implantation, the mice were imaged weekly using 
IVIS Spectrum In Vivo Imaging System. After 28 days, the mice were sacrificed due to the tumor burden; B) Representative orthotopic xenograft 
experiment, following the injection of ten nude mice with MBShh daoy-luc cells (105 cells), previously infected with a lentiviral particle (100 Moi) 
encoding Firefly Luciferase gene (Redifect Red.Fluc-Puro, CLS960002, by Perkin Elmer), within the fourth ventricle of nude mice (ten mice were 
used); C) BLI analysis of photon emission from the cerebellum of the mice orthotopically injected with MBShh daoy-luc cells was performed using 
the statistic software SPSS. Bli images were taken weekly from the time of implantation (from T0 to T4). The trend of the tumor growth is presented 
in the Box-Plot generated with SPSS software. The differences in Total Flux (photon per second) are statistically significant from the second week 
from the implantation with respect to T0 (P-value <0.05). in details, the values from T2, T3 and T4 were compared with T0; d) hematoxylin/eosin 
staining of cerebellar tumors generated by implanting daoy-luc cells into the fourth ventricle of nude mice was shown (5X, 20X and 40X). The 
staining detects the presence of tumorigenic cells and the tumor burden within the cerebellum of the implanted mice.
a
dB
c
Table I.—Total flux values from MBSHH DAOY orthotopic xenograft models.
Mice number
Mean log2 [tot flux (p/s)]
T-0 T-1 T-2 T-3 T-4
1 1.52e+01 1.65e+01 1.75e+01 1.98e+01 2.33e+01
2 1.55e+01 1.62e+01 1.75e+01 1.90e+01 2.09e+01
3 1.58e+01 1.76e+01 1.84e+01 1.93e+01 1.98e+01
4 1.63e+01 1.80e+01 1.84e+01 1.93e+01 1.98e+01
5 1.68e+01 1.67e+01 1.72e+01 1.90e+01 2.07e+01
6 1.72e+01 1.65e+01 1.68e+01 1.79e+01 1.79e+01
7 1.69e+01 1.64e+01 1.68e+01 1.73e+01 1.87e+01
8 1.77e+01 1.87e+01 1.85e+01 1.93e+01 2.00e+01
9 1.79e+01 1.94e+01 2.01e+01 2.07e+01 2.15e+01
10 1.85e+01 1.95e+01 1.98e+01 2.12e+01 2.17e+01
The quantified bioluminescence values (photons per sec) are reported in the table. Mice (1-10) were imaged weekly (from T0 to T4), and tumor growth was evaluated 
by acquisitions of bioluminescence imaging (BLI) using IVIS 3D Illumina Imaging System. The integrated fluxes of photons (photons per sec) within each region of 
interest (roi) were determined using the living images Software Package 3.2 (Xenogen-caliper, alameda, ca, uSa).
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distinct, they should be targeted individually. it should 
be important to have murine models representative of all 
the molecular subtypes to test novel targeted therapies 
in appropriate animal models. human gene expression 
signatures faithfully replicate the biology of primary tu-
mors from which they are derived.36 This supports the 
use of subgroup specific orthotopic MB PDX models 
for preclinical drug screenings for MB treatment.
in conclusion, orthotopic MB PdX models could 
overcome the limits of geM and orthotopic xenograft 
models. The challanges of PDX are the difficulties for 
the orthotopic primary tumors implantation and for the 
following of tumorigenesis in vivo. Their use requires 
molecular imaging studies to verify the location of tu-
mor grafts after implantation. The growing develop-
ment of molecular imaging will allow us to develop 
novel drugs, specific for MB molecular subgroups using 
these MB PdX orthotopic models, to obtain a very high 
predictive clinical response.
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in terms of tumor growth/regression. The introduction 
of natural agents into cancer treatments is emerging a 
helpful strategy that meets the need to develop novel 
antitumorigenic drugs with low toxicity.32 recently, 
the antitumorigenic action of Norcantharidin, a natural 
compound belonging to the most emergent antitumori-
genic agents,32 has been found to inhibit the growth of 
intra-cerebellum tumors in vivo using orthotopic MB 
xenograft mice by measuring bioluminescence emis-
sion (Bli) levels.33 This preclinical study, using Bli 
method, enhances the potential for the future use of this 
natural compound to treat children affected by MB.
Bli technologies have been also used to study the 
synergistic combination of novel antitumorigenic drugs 
and radiotherapy. Through the use of Bli, the role of 
celecoxib, a selective coX-2 inhibitor, in enhanc-
ing the effects of ionizing radiotherapy (ir) on tumor 
growth has also been described in orthotopic MB xe-
nografts.34
Bli tecnique is also of importance for translational 
research on MB metastases, which are the primary 
cause of treatment failure in MB. To this purpose, Bli 
method has been applied to generate an experimental 
mouse model simulating the leptomeningeal dissemi-
nation (seeding) of MB by intra-cisternal inoculation 
of human MB cells.35 importantly, through Bli, these 
“metastatic MB cells” can be monitored in vivo dur-
ing the spreading and the seeding. The establishment 
of this MB seeding model 35 through the use of Bli, is 
a valuable resource for future translational research to 
test novel antimetastatic drugs on the extent of tumor 
spread in live condition, especially for the treatment of 
metastatic MBgroup3/group4, as recently demonstrated.31
Conclusions
In vivo Bli technology in geM, orthotopic xeno-
grafts and PdX models, is useful for enhancing our 
understanding of MB development and treatment. 
geM are useful models for examining the role of spe-
cific genes during tumor development and progression, 
while the orthotopic xenograft and PdX models are 
more suitable for predicting drug response to novel an-
ticancer therapeutics.
however, most novel anticancer therapeutics fail, 
upon reaching Phase iii clinical trials. Because MB 
subtypes are clinically, transcriptionally and genetically 
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